Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information...
Cheers
Ulf
2.15.2011
A new Value Based Pricing research paper from York
Dear Readers,
a colleague of mine just pointed out a new paper on value based pricing from the University of York. The NHS consultation period is ongoing and am sure we will see a lot more papers and discussion on the topic. Stay tuned! Ciao Ulf
No comments:
Post a Comment